capecitabine,mitomycin
Not Tagged
[]
ctdna in anal cancer. n=31. baseline ctdna detectable in 88% of pts w 94% going to molecular remission, which preceded ccr. no patients have recurred -can't say if ctdna useful in surveillance (i'd bet early local recurrences aren't shedding ctdna, let's see). #gi23 
GI Radiation Oncologist | Beijing, Newton MA, @Princeton, @harvardmed, now @UTSouthwestern | buying in bulk | @AAAS IF/THEN | Tweets=own | FCOI: https://t.co/EjwMnJKbth